Current therapy and drug resistance in metastatic castration-resistant prostate cancer

被引：141

作者：

Cai, Maoping ^{[1
,2
,3
]}

Song, Xian-Lu ^{[4
]}

Li, Xin-An ^{[5
]}

Chen, Mingkun ^{[1
,2
,6
]}

Guo, Jiading ^{[1
,2
]}

Yang, Dong Hua ^{[7
]}

Chen, Zhanghui ^{[3
]}

Zhao, Shan-Chao ^{[1
,2
,6
]}

机构：

[1] Southern Med Univ, Affiliated Hosp 3, Dept Urol, Guangzhou 510630, Guangdong, Peoples R China

[2] Southern Med Univ, Clin Coll 3, Guangzhou 510630, Guangdong, Peoples R China

[3] Cent Peoples Hosp Zhanjiang, Zhanjiang Inst Clin Med, Zhanjiang 524045, Guangdong, Peoples R China

[4] Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Dept Radiotherapy, Guangzhou 510095, Guangdong, Peoples R China

[5] Guangzhou Med Univ, Sch Basic Med Sci, Guangzhou 511436, Guangdong, Peoples R China

[6] Southern Med Univ, Nanfang Hosp, Dept Urol, Guangzhou 510515, Guangdong, Peoples R China

[7] New York Coll Tradit Chinese Med, Mineola, NY 11501 USA

来源：

DRUG RESISTANCE UPDATES | 2023年 / 68卷

基金：

中国国家自然科学基金;

关键词：

Metastatic castration -resistance prostate cancer; (mCRPC); Drug resistance; Chemotherapy; Androgen receptor signaling inhibitors (ARSIs); Poly (ADP -ribose) polymerase (PARP); inhibitors (PARPi); DOUBLE-BLIND; TUMOR HETEROGENEITY; ABIRATERONE ACETATE; PLUS PREDNISONE; ANDROGEN-DEPRIVATION; INCREASED SURVIVAL; CLINICAL-OUTCOMES; ZOLEDRONIC ACID; BONE METASTASES; DOCETAXEL;

D O I：

10.1016/j.drup.2023.100962

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Castration-resistant prostate cancer (CRPC), especially metastatic castration-resistant prostate cancer (mCRPC) is one of the most prevalent malignancies and main cause of cancer-related death among men in the world. In addition, it is very difficult for clinical treatment because of the natural or acquired drug resistance of CRPC. Mechanisms of drug resistance are extremely complicated and how to overcome it remains an urgent clinical problem to be solved. Thus, a comprehensive and thorough understanding for mechanisms of drug resistance in mCRPC is indispensable to develop novel and better therapeutic strategies. In this review, we aim to review new insight of the treatment of mCRPC and elucidate mechanisms governing resistance to new drugs: taxanes, androgen receptor signaling inhibitors (ARSIs) and poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi). Most importantly, in order to improve efficacy of these drugs, strategies of overcoming drug resistance are also discussed based on their mechanisms respectively.

引用

页数：11

共 126 条

[1] Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration [J].

Abida, Wassim ;

Patnaik, Akash ;

Campbell, David ;

Shapiro, Jeremy ;

Bryce, Alan H. ;

McDermott, Ray ;

Sautois, Brieuc ;

Vogelzang, Nicholas J. ;

Bambury, Richard M. ;

Voog, Eric ;

Zhang, Jingsong ;

Piulats, Josep M. ;

Ryan, Charles J. ;

Merseburger, Axel S. ;

Daugaard, Gedske ;

Heidenreich, Axel ;

Fizazi, Karim ;

Higano, Celestia S. ;

Krieger, Laurence E. ;

Sternberg, Cora N. ;

Watkins, Simon P. ;

Despain, Darrin ;

Simmons, Andrew D. ;

Loehr, Andrea ;

Dowson, Melanie ;

Golsorkhi, Tony ;

Chowdhury, Simon .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (32) :3763-+

[2]

Aggarwal R.R., 2015, AM SOC CLIN ONCOL

[3] Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer [J].

Annala, Matti ;

Vandekerkhove, Gillian ;

Khalaf, Daniel ;

Taavitsainen, Sinja ;

Beja, Kevin ;

Warner, Evan W. ;

Sunderland, Katherine ;

Kollmannsberger, Christian ;

Eigl, Bernhard J. ;

Finch, Daygen ;

Oja, Conrad D. ;

Vergidis, Joanna ;

Zulfiqar, Muhammad ;

Azad, Arun A. ;

Nykter, Matti ;

Gleave, Martin E. ;

Wyatt, Alexander W. ;

Chi, Kim N. .

CANCER DISCOVERY, 2018, 8 (04) :444-457

[4] Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study [J].

Antonarakis, Emmanuel S. ;

Piulats, Josep M. ;

Gross-Goupil, Marine ;

Goh, Jeffrey ;

Ojamaa, Kristiina ;

Hoimes, Christopher J. ;

Vaishampayan, Ulka ;

Berger, Ranaan ;

Sezer, Ahmet ;

Alanko, Tuomo ;

de Wit, Ronald ;

Li, Chunde ;

Omlin, Aurelius ;

Procopio, Giuseppe ;

Fukasawa, Satoshi ;

Tabata, Ken-ichi ;

Park, Se Hoon ;

Feyerabend, Susan ;

Drake, Charles G. ;

Wu, Haiyan ;

Qiu, Ping ;

Kim, Jeri ;

Poehlein, Christian ;

de Bono, Johann Sebastian .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)

[5] Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade [J].

Arora, Vivek K. ;

Schenkein, Emily ;

Murali, Rajmohan ;

Subudhi, Sumit K. ;

Wongvipat, John ;

Balbas, Minna D. ;

Shah, Neel ;

Cai, Ling ;

Efstathiou, Eleni ;

Logothetis, Chris ;

Zheng, Deyou ;

Sawyers, Charles L. .

CELL, 2013, 155 (06) :1309-1322

[6]

Barber L.J., 2013, J PATHOL

[7] Tumour heterogeneity in the clinic [J].

Bedard, Philippe L. ;

Hansen, Aaron R. ;

Ratain, Mark J. ;

Siu, Lillian L. .

NATURE, 2013, 501 (7467) :355-364

[8] Microtubule-targeted anticancer agents and apoptosis [J].

Bhalla, KN .

ONCOGENE, 2003, 22 (56) :9075-9086

[9] Studying clonal dynamics in response to cancer therapy using high-complexity barcoding [J].

Bhang, Hyo-eun C. ;

Ruddy, David A. ;

Radhakrishna, Viveksagar Krishnamurthy ;

Caushi, Justina X. ;

Zhao, Rui ;

Hims, Matthew M. ;

Singh, Angad P. ;

Kao, Iris ;

Rakiec, Daniel ;

Shaw, Pamela ;

Balak, Marissa ;

Raza, Alina ;

Ackley, Elizabeth ;

Keen, Nicholas ;

Schlabach, Michael R. ;

Palmer, Michael ;

Leary, Rebecca J. ;

Chiang, Derek Y. ;

Sellers, William R. ;

Michor, Franziska ;

Cooke, Vesselina G. ;

Korn, Joshua M. ;

Stegmeier, Frank .

NATURE MEDICINE, 2015, 21 (05) :440-U207

[10] Overview of the latest treatments for castration-resistant prostate cancer [J].

Bishr, Mohamed ;

Saad, Fred .

NATURE REVIEWS UROLOGY, 2013, 10 (09) :522-528

← 1 2 3 4 5 6 7 8 9 10 →